fenfluramine has been researched along with Prader-Willi Syndrome in 2 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind trial was conducted to determine the effect of fenfluramine on the weight and behaviour of patients with the Prader-Willi syndrome." | 9.06 | Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. ( Pendergast, A; Selikowitz, M; Sunman, J; Wright, S, 1990) |
| "A double blind trial was conducted to determine the effect of fenfluramine on the weight and behaviour of patients with the Prader-Willi syndrome." | 5.06 | Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. ( Pendergast, A; Selikowitz, M; Sunman, J; Wright, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tu, JB | 1 |
| Hartridge, C | 1 |
| Izawa, J | 1 |
| Selikowitz, M | 1 |
| Sunman, J | 1 |
| Pendergast, A | 1 |
| Wright, S | 1 |
1 trial available for fenfluramine and Prader-Willi Syndrome
| Article | Year |
|---|---|
Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
Topics: Adolescent; Adult; Body Weight; Child; Child Behavior; Child, Preschool; Double-Blind Method; Female | 1990 |
1 other study available for fenfluramine and Prader-Willi Syndrome
| Article | Year |
|---|---|
Psychopharmacogenetic aspects of Prader-Willi syndrome.
Topics: Adolescent; Aggression; Appetite Depressants; Behavior Therapy; Carbamazepine; Combined Modality The | 1992 |